All Blogs
Oct 31, 2025
Pharma Rivalry Intensifies: Novo Nordisk Looks to Wrest Metsera from Pfizer
In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker Novo Nordisk launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer had already secured. The aggressive counteroffer, announced on October 30, 2025,...
Read More...
Oct 30, 2025
Zimmer Biomet Wins FDA Breakthrough Status for Iodine-Treated Hip Implant; Terumo Gains U.S. Clearance for OPUSWAVE® System and DualView® Catheter; Medtronic’s Symplicity Spyral RDN Device Added to CMS National Coverage; West Launches Synchrony™ PFS System at CPHI; Emboline Completes U.S. Pivotal IDE Trial Enrollment for Emboliner® Device; Laborie Completes First Procedures in ENDURE 1 Trial with Optilume® Balloon
Zimmer Biomet Announced FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System On October 28, 2025, Zimmer Biomet Holdings, Inc., a global leader in medical technology, announced that the FDA had granted breakthrough device designation for its groundbreaking iodine-treat...
Read More...
Oct 29, 2025
Artificial Intelligence in Drug Commercialization: Accelerating Market Success through Data-Driven Precision
The pharmaceutical industry is undergoing a paradigm shift, as Artificial Intelligence (AI) becomes a central force in transforming every stage of the drug lifecycle, from discovery to post-market performance. Among its most disruptive applications, AI in drug commercialization is redefining how therapies are...
Read More...
Oct 28, 2025
Syndax Pharmaceuticals Receives FDA Approval for REVUFORJ; FDA Approves BLENREP for Adults with Relapsed/Refractory Multiple Myeloma; Novartis to Acquire Avidity for $12 Billion; BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study; Eli Lilly to Acquire Adverum Biotechnologies
Syndax Pharmaceuticals Receives Approval for REVUFORJ from the FDA Syndax Pharmaceuticals announced that the FDA has approved REVUFORJ (revumenib) for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and old...
Read More...
Oct 27, 2025
Roche’s GAZYVA Extends Indications Into Lupus, Strengthening Immunology Pipeline
As the lupus treatment landscape undergoes major changes, Roche is entering the US lupus nephritis market with a fresh FDA approval for its long-standing blood cancer drug, GAZYVA. On October 20, 2025, Roche’s Genentech division announced that the FDA had approved GAZYVA (obinutuzumab) for use in adults with active...
Read More...
Oct 23, 2025
OncoHost Granted New York State Lab Permit, Enabling PROphetNSCLC® Nationwide Access; Onkos Surgical’s ELEOS Proximal Tibia with NanoCept antibacterial surface receives FDA 510(k) clearance; BD’s Simplified At-Home HPV Test to Expand Cervical Cancer Screening Internationally; Oticon’s New Zeal™ Hearing Aid Delivers Discreet Style with Next-Gen AI Sound & Connectivity; Nyra Medical Launches First-in-Human Trial of New Mitral Valve Repair System; Cordis Reveals 12-Month Outcomes from SELUTION SLR DEB Trial
OncoHost Received New York State Laboratory Permit, Expanding Availability of PROphetNSCLC® Precision Oncology Test On October 22, 2025, OncoHost, a technology company transforming the approach to precision medicine through plasma proteomics and AI, announced that it had received a laboratory permit from t...
Read More...
Oct 22, 2025
The AI Drug Discovery Revolution: Smarter Science, Faster Therapies, Better Outcomes
The pharmaceutical industry has always been a high-stakes arena, where years of research, billions of dollars, and countless clinical trials culminate in a single therapy reaching patients. Despite tremendous advancements, the traditional drug discovery process remains time-consuming, costly, and fraught with uncer...
Read More...
Oct 24, 2025
4 Investigational Chronic Pruritus Drugs Shaping the Treatment Landscape
The chronic pruritus drugs market is currently not highly competitive, with only a few chronic pruritus drugs approved for treatment, including KORSUVA/KAPRUVIA (Cara Therapeutics/CSL/ Vifor/Maruishi), LIVMARLI (Mirum Pharmaceuticals/Takeda), and BYLVAY/KAYFANDA (Mirum Pharmaceuticals/Takeda). However, the treatmen...
Read More...
Oct 21, 2025
FDA Approves Genentech’s GAZYVA for Lupus Nephritis; Glaukos’ EPIOXA Wins FDA Approval for Keratoconus Treatment; FDA Accepts Replimune’s RP1 BLA Resubmission for Advanced Melanoma; Cogent’s Bezuclastinib Earns FDA Breakthrough Therapy for SM-AHN; Amgen’s TEZSPIRE Gets FDA Nod for Chronic Rhinosinusitis with Nasal Polyps
FDA Approves Genentech’s GAZYVA for Lupus Nephritis Genentech, a member of the Roche Group, announced that the FDA has approved GAZYVA (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) receiving standard therapy. The approval is supported by data from the Phase II NOBILITY and P...
Read More...
Oct 20, 2025
Peanut Allergy Treatment Space: Expanding Horizons Beyond Traditional Immunotherapy
Peanut allergy is among the most common and serious types of food allergy, with prevalence increasing over the past few decades, particularly among younger populations. It usually first appears in childhood, with symptoms emerging as early as 4 months of age and most often within the first two years of life. Around...
Read More...